AVITA Medical 第四季度每股收益 $(0.44) 未达预期 $(0.43),销售额 $18.41M 低于预期 $21.04M

财报速递2025-02-14
AVITA Medical(纳斯达克股票代码:RCEL)报告其季度每股亏损为 $(0.44),低于分析师一致预期的 $(0.43),差距为2.33%。与去年同期每股亏损$(0.28)相比,这一数字下降了57.14%。公司报告季度销售额为$18.41百万,低于分析师一致预期的$21.04百万,差距为12.53%。与去年同期的$14.20百万销售额相比,本季度销售额增长了29.67%。

以上内容来自Benzinga Earnings专栏,原文如下:

AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 57.14 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $18.41 million which missed the analyst consensus estimate of $21.04 million by 12.53 percent. This is a 29.67 percent increase over sales of $14.20 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法